Exagen Inc. (XGN)

NASDAQ: XGN · IEX Real-Time Price · USD
1.542
-0.018 (-1.15%)
Mar 28, 2024, 1:56 PM EDT - Market open

Company Description

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States.

The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.

The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS.

In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease.

Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.

It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers.

The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019.

Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Exagen Inc.
Exagen logo
Country United States
IPO Date Sep 19, 2019
Industry Diagnostics & Research
Sector Healthcare
Employees 174
CEO John Aballi

Contact Details

Address:
1261 Liberty Way
Vista, California 92081
United States
Phone (760) 560-1501
Website exagen.com

Stock Details

Ticker Symbol XGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001274737
CUSIP Number 30068X103
ISIN Number US30068X1037
SIC Code 8071

Key Executives

Name Position
Dr. Tina S. Nova Ph.D. Executive Chairman of the Board of Directors
John Aballi Chief Executive Officer, President and Director
Kamal Adawi M.S., MBA Chief Financial Officer and Corporate Secretary
Ryan Douglas Investors Relations Officer
John Wegener Senior Vice President of Sales and Marketing
Dr. Andrew L. Concoff FACR, M.D. Chief Innovation Officer and Member of Rheumatoid Arthritis Scientific Advisory Board
Dr. Michael I. Nerenberg M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 18, 2024 10-K Annual Report
Mar 18, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 8, 2024 8-K Current Report